Jason Luoma, Ph.D.
banner
jasonluoma.bsky.social
Jason Luoma, Ph.D.
@jasonluoma.bsky.social
Psychedelics, MDMA, and shame researcher, treatment developer, author, psychologist, and therapy trainer, at the Portland Institute for Psychedelic Science.
🧵 First clinical trial ever conducted in a state-regulated psychedelic program just published. Oregon's psilocybin program has served 20,000+ people but the majority are wealthy out-of-state travelers. This study targeted low-income participants to test feasibility. #psychedelicscience
February 17, 2026 at 12:08 AM
Reposted by Jason Luoma, Ph.D.
approval to study psilocybin/COMP360 assisted therapy for PTSD

we shall see if it is more effective than MDMA

www.lucid.news/legislation-...
Legislation, Industry, and the Future of Psilocybin for PTSD - Lucid News
The FDA acceptance of Compass Pathway’s Investigational New Drug Application for their COMP360 compound as a possible therapy for PTSD introduces a new area of possible therapies using psilocybin.
www.lucid.news
February 13, 2026 at 5:55 PM
Psychedelics are FDA "breakthrough therapies" - but breakthrough for whom? New analysis reveals 85% of US psychedelic trial participants are non-Hispanic White, raising urgent questions about who actually benefits from this "revolution" in mental health. 🧵 #psychedelicscience
February 11, 2026 at 11:47 PM
Important new Nature Medicine review talks about the two neuroscience mechanisms related to psychedelics that appear to be replicating across species, brain scales, and research labs.

The story: Acute chaos + lasting plasticity = therapeutic change 🧵#psychedelicscience
February 10, 2026 at 8:56 PM
🌿 Announcing the 2026 Perspective Psychedelic Training Retreat for healthcare professionals
July 3-10, 2026 | Netherlands
A week-long immersive training in psychedelic-assisted therapy grounded in ACT.
Applications open now: perspectiveretreats.com/application-process
Application Process | Perspective
perspectiveretreats.com
February 8, 2026 at 6:59 PM
Reposted by Jason Luoma, Ph.D.
After being held in two of them as a boy, I fought for decades urging America to never again build concentration camps and put human beings in them. It breaks my heart to watch this happen twice now in my own lifetime.
January 27, 2026 at 9:30 PM
Reposted by Jason Luoma, Ph.D.
🧪IMPORTANT! This graphic explains how science all over the US is funded. Congress approved a 2% increase in the #NIH budget for FY 26.

Buried in the bill-
Shift of ~40% of grants to MYF. This will still result in a 35% DECREASE in the NUMBER of grants funded per yr.

Russel Vought is behind this.
January 22, 2026 at 1:25 AM
Fun 2025 post about random facts zhengdongwang.com/2025/12/21/t...
The best facts I heard this year
Zhengdong Wang’s personal website
zhengdongwang.com
January 1, 2026 at 5:47 PM
Reposted by Jason Luoma, Ph.D.
Psychedelics don’t require ethical exemptions. We argue against “ethical exceptionalism” while supporting context-sensitive policies that uphold shared research and clinical standards. Distinctive effects ≠ new ethics.

OA Link: www.researchgate.net/publication/...
(PDF) Are Psychedelics Ethically Exceptional After All? Some Further Reflections
PDF | In this response to commentators on our target article, we clarify and refine our position on claims of psychedelic ethical exceptionalism.... | Find, read and cite all the research you need on…
www.researchgate.net
December 30, 2025 at 8:43 AM
Our clinical research postdoc in psychedelic science is still receiving applications through January 6th! Come join our awesome team! share.google/8eoBuA33dYa1...
Postdoctoral Research Fellowship in Clinical Psychedelic Science - Portland Psychotherapy
The Portland Institute for Psychedelic Science and Portland Psychotherapy Clinic, Research, & Training Center are offering a two-year research Postdoctoral Research Fellowship in Clinical Psychedelic ...
share.google
December 23, 2025 at 2:47 PM
Great to see some studies coming out on psilocybin for PTSD. Lots of facilitators in Oregon are using psilocybin to treat PTSD, but so far we are lacking data. Only one previous open label trial has been published that I know of. The authors just published a qualitative study from that study. A🧵
December 23, 2025 at 12:10 AM
Ive seen this in papers I've reviewed. People, you can't trust the references that chatgpt generates! That's not how llms work.
search.app/CRgw2
AI Is Inventing Academic Papers That Don't Exist -- And They're Being Cited in Real Journals
Academic articles from authors using large language model are creating an ecosystem of fake research that threatens human knowledge itself.
search.app
December 18, 2025 at 1:29 PM
New psilocybin cognition study shows "significant improvements" in processing speed & executive function after treatment.

But dig into the data and the picture gets complicated.

A thread on why statistical significance does not equal clinical meaningfulness 🧵

#psychedelicscience
December 17, 2025 at 3:50 PM
Reposted by Jason Luoma, Ph.D.
🐁 Very concerning finding: Psilocybin promotes brain tumour growth

Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed."

Extends to other serotonergic drugs like LSD.
December 15, 2025 at 3:47 PM
Another article about Oregon’s psilocybin system for those interested. From my vantage point seems like the system is relatively stable but probably shrinking some from increased competition from Colorado. Fewer people from the Midwest and east coast these days.
December 13, 2025 at 4:24 PM
Reposted by Jason Luoma, Ph.D.
This new @michellemonje.bsky.social preprint shows that #psilocybin promotes the rapid and persistent growth of... xenografted glioma in mice. 🫠

www.biorxiv.org/content/10.6...

Enduring but maladaptive plasticity induced by #psychedelics.

h/t @tylerekins.bsky.social @theborislab.bsky.social
December 13, 2025 at 2:04 PM
Seems like the The "Memory Wars" are coming back - now with psychedelics. A few studies coming out, this one showing 42% of people with post-psychedelic difficulties linked them to childhood trauma.

Centrally, some said they recovered memories they had NO prior recollection of.

#psychedelicscience
December 5, 2025 at 3:30 PM
Reposted by Jason Luoma, Ph.D.
Critical commentary on a recent paper reporting emergence of dissociated traumatic memories during psilocybin treatment now out in the Journal of Eating Disorders, with @trpwolff.bsky.social, @manojdoss.bsky.social, Lilian Kloft-Heller, and @henryotgaar.bsky.social.

doi.org/10.1186/s403...
Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa” - Journal of Eating Disorders
In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilocybin treatment for anorexia nervosa. These case reports are of clinical and scientific interest and confirm that psychedelics may induce vivid memory-like experiences. However, the reports warrant scrutiny. Here, based on what is known about recovered memories and the effects of psychedelics, we argue that the authors may not have adequately considered alternative explanations. The cases do not necessarily demonstrate that psilocybin induces recovery of dissociated traumatic memories or could treat dissociative amnesia. We further caution against the authors’ suggestion of explicitly preparing patients for the emergence of forgotten material.
doi.org
December 4, 2025 at 7:47 AM
Looks like we have a 7th placebo controlled trial on microdosing psychedelics showing microdosing did not outperform placebo, this time for depression. #psychedelicscience www.linkedin.com/posts/justin...
Microdosing in Depression Trial Initial Results | Justin Hanka | 17 comments
I'm still in disbelief! 😯 After so many years of clinical trials and hope for this treatment for depression, the initial results are in, and its not what we expected or hoped for, but we learned a ...
www.linkedin.com
November 27, 2025 at 8:47 PM
Two more rigorous placebo-controlled trials just came out that were negative on microdosing, this time with psilocybin. I think these are the 5th and 6th RCTs with negative results. NO cognitive or mood benefits compared to placebo. 🧵 #psychedelicscience
November 14, 2025 at 1:12 PM
I had missed this interesting podcast from 2023 with Matt Johnson at Johns Hopkins, talking about his history of psychedelic research and thoughts on his groundbreaking study on psilocybin-assisted therapy for smoking cessation. #psychedelicscience
November 11, 2025 at 3:20 PM
A comprehensive living systematic review on psychedelics & MDMA for mental disorders just launched - this a really important new resource for tracking the evidence in real-time. #psychedelicscience
EBI-PSYCHE | Home
ebipsyche-database.org
November 10, 2025 at 5:48 PM
Super important new paper on reports of challenging experiences by therapists who have participated in research trials of psychedelic-assisted therapy. Reveals huge rift between what providers believe is necessary and what industry is developing as a standard. #psychedelicscience
October 30, 2025 at 4:01 PM
Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA

10.1093/brain/awaf391
October 27, 2025 at 3:33 AM
New review says that after 55+ years of psychedelic research, we have very few empirical studies on music selection for psychedelic-assisted therapy—despite experts calling music central to therapeutic outcomes. #psychedelicscience
October 18, 2025 at 11:07 PM